1. Scrip

Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook

 
• By Joseph Haas

Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.

Coronavirus with cardio lines, cellular designs and lungs
Oral antiviral shows ability to reduce risk of COVID-19 hospitalization and death

Phase III data on Merck & Co., Inc. and Ridgeback Biotherapeutics LP's oral ribonucleoside analog molnupiravir are being hailed as a transformative event for the COVID-19 pandemic, since an oral antiviral therapy that can lessen disease severity could have more impact than the injectable/infused therapies that have come before it.

The partners released interim data on 1 October showing molnupiravir reduced the risk of hospitalization or death in COVID-19-infected people with mild-to-moderate cases by nearly 50% compared to placebo

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip